<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-sub-section" /><meta name="keywords" content="Progestogens: contraceptives: parenteral; Contraception: parenteral; Medroxyprogesterone: contraception; Depo-Provera; Norethisterone enantate; Noristerat; Nexplanon; Etonogestrel: implant; Contraception: implants; Implanon" /><meta name="IX" content="Progestogens: contraceptives: parenteral; Contraception: parenteral; Medroxyprogesterone: contraception; Depo-Provera; Norethisterone enantate; Noristerat; Nexplanon; Etonogestrel: implant; Contraception: implants; Implanon" /><title>7.3.2.2 Parenteral progestogen-only contraceptives: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="4580.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="4580.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=4580.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2074.htm">7 Obstetrics, gynaecology, and urinary-tract disorders</a> &gt; <a href="4551.htm">7.3 Contraceptives</a> &gt; <a href="4571.htm">7.3.2 Progestogen-only contraceptives</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="4573.htm" title="Previous: ORAL PROGESTOGEN-ONLY CONTRACEPTIVES">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="13748.htm" title="Next: PARENTERAL PROGESTOGEN-ONLY CONTRACEPTIVES">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_4580">7.3.2.2 Parenteral progestogen-only contraceptives</h1><?highlighter on?><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i664.htm" title="Go to appendix 1">Progestogens</a>).</div><div><div id="_4580.1"><p><b><span>Medroxyprogesterone
acetate</span></b> (<span class="cZ">Depo-Provera</span>®) is a long-acting progestogen
given by intramuscular injection; it is as effective as the combined
oral preparations but because of its prolonged action it should never be given without <i>full counselling backed by
the patient information leaflet</i>. It may be
used as a short-term or long-term contraceptive for women who have
been counselled about the likelihood of menstrual disturbance and
the potential for a delay in return to full fertility. Delayed return
of fertility and irregular cycles may occur after discontinuation
of treatment but there is no evidence of permanent infertility. Troublesome
bleeding has been reported in patients given medroxy<span>progesterone</span> acetate in the immediate puerperium; delaying the first injection
until 6 weeks after birth may minimise bleeding problems. If the woman
is not breast-feeding, the first injection may be given within 5 days
postpartum (she should be warned that the risk of heavy or prolonged
bleeding may be increased). The manufacturer advises that in women
who are breast-feeding, the first dose should be delayed until 6 weeks
after birth; however, evidence suggests no harmful effect to infant
if given earlier. The benefits of using medroxyprogesterone acetate
in breast-feeding women outweigh any risks.</p><p>Reduction in bone mineral density and, rarely, osteoporosis
and osteoporotic fractures have also been reported with medroxyprogesterone
acetate. The reduction in bone mineral density occurs in the first
2–3 years of use and then stabilises. See also below. </p><div class="cN"><ul class="cBF"><li><p class="cQ">In adolescents, <span>medroxyprogesterone
acetate</span> (<span class="cZ">Depo-Provera</span>®) should be used
only when other methods of contraception are inappropriate;</p></li><li><p class="cQ"> in all women, the benefits of using <span>medroxyprogesterone acetate</span> beyond 2 years should be evaluated
against the risks;</p></li><li><p class="cQ"><span id="_4580.5">in women with risk factors for osteoporosis, a method of contraception
other than <span>medroxyprogesterone acetate</span> should be
considered.</span></p></li></ul></div></div><div id="_4580.2"><p><b><span>Norethisterone</span> enantate</b> (<span class="cZ">Noristerat</span>®) is a long-acting progestogen
given as an oily injection which provides contraception for 8 weeks;
it is used as short-term interim contraception e.g. before vasectomy
becomes effective. </p></div><div id="_4580.3"><p> An <b>etonogestrel-releasing
implant</b> (<span class="cZ">Nexplanon</span>®) is also available.
It is a highly effective long-acting contraceptive, consisting of
a single flexible rod that is inserted subdermally into the lower
surface of the upper arm and provides contraception for up to 3 years. The manufacturer advises that in heavier women, blood-<span>etonogestrel</span> concentrations are lower and therefore the implant may not provide
effective contraception during the third year; they advise that earlier
replacement may be considered in such patients—however, evidence to
support this recommendation is lacking. Local reactions
such as bruising and itching can occur at the insertion site. The
contraceptive effect of etonogestrel is rapidly reversed on removal
of the implant. <i>The doctor or nurse administering (or removing) the system
should be fully trained in the technique and should provide full counselling
reinforced by the patient information leaflet</i>.</p><p><span class="cZ">Implanon</span>®, also an etonogestrel-releasing implant, has
been discontinued (October 2010), but some women may have the implant
in place until 2013.</p></div><div class="cAZ"><h2>Cautions, contra-indications, and side-effects</h2> <p class="cAX">The <a title="target-block: Oral progestogen-only contraceptives cautions" href="4573.htm#_200137">cautions</a>, <a title="target-block: Oral progestogen-only contraceptives contra-indications" href="4573.htm#_200141">contra-indications</a>, and <a title="target-block: Oral progestogen-only contraceptives side-effects" href="4573.htm#_200143">side-effects</a> of oral
progestogen-only contraceptives apply to parenteral progestogen-only
contraceptives, except that parenteral preparations reliably inhibit
ovulation and therefore protect against ectopic pregnancy and functional
ovarian cysts.</p></div><div id="_4580.4"><div class="cAZ"><h2>Interactions</h2> <p class="cAX">Effectiveness of <span>parenteral
progestogen-only contraceptives</span> is not affected by antibacterials
that do not induce liver enzymes. The effectiveness of norethisterone
and medroxyprogesterone acetate intramuscular injections is not affected
by enzyme-inducing drugs and they may be continued as normal during
courses of these drugs. However, effectiveness of the
etonogestrel-releasing implant may be reduced by enzyme-inducing drugs and an alternative contraceptive method, unaffected by the interacting
drug, is recommended during treatment with the enzyme-inducing drug
and for at least 4 weeks after stopping. For a short course of an
enzyme-inducing drug, if a change in contraceptive method is undesirable
or inappropriate, the implant may be continued in combination with
additional contraceptive precautions (e.g. condom) for the duration
of treatment with the enzyme-inducing drug and for 4 weeks after stopping
it.</p></div></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_13748"><a href="13748.htm" title="PARENTERAL PROGESTOGEN-ONLY CONTRACEPTIVES">PARENTERAL PROGESTOGEN-ONLY CONTRACEPTIVES</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="4573.htm">Previous: ORAL PROGESTOGEN-ONLY CONTRACEPTIVES</a> | <a class="top" href="4580.htm#">Top</a> | <a accesskey="]" href="13748.htm">Next: PARENTERAL PROGESTOGEN-ONLY CONTRACEPTIVES</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>